TY  - GEN
AU  - Agus,David B
AU  - Sweeney,Christopher J
AU  - Morris,Michael J
AU  - Mendelson,David S
AU  - McNeel,Douglas G
AU  - Ahmann,Frederick R
AU  - Wang,Jin
AU  - Derynck,Mika K
AU  - Ng,Kimmie
AU  - Lyons,Benjamin
AU  - Allison,David E
AU  - Kattan,Michael W
AU  - Scher,Howard I
TI  - Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
SN  - 1527-7755
PY  - 2007///0327
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Bridged-Ring Compounds
KW  - adverse effects
KW  - Disease Progression
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Drug Resistance, Neoplasm
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - drug therapy
KW  - Orchiectomy
KW  - Probability
KW  - Prognosis
KW  - Prostatic Neoplasms
KW  - Receptor, ErbB-2
KW  - Risk Assessment
KW  - Single-Blind Method
KW  - Survival Analysis
KW  - Taxoids
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2006.07.0649
ER  -